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Abstract We investigated the localization of histidine decar-
boxylase (HDC), which is the rate-limiting enzyme that
generates histamine from histidine, in human aorta/coronary
artery. RT-PCR and immunohistochemical staining revealed
that the HDC gene was expressed in monocytes/macrophages
and T cells in the arterial intima but not in smooth muscle cells in
either the arterial intima or the media. A luciferase promoter
assay with U937 and Jurkat cells demonstrated that interleukin-
4 (IL-4) inhibited the expression of the HDC gene. In contrast,
among a scavenger receptor family, IL-4 as well as histamine up-
regulated U937 cells to express the LOX-1 gene but not the SR-
A gene, which genes encode receptors that scavenge oxidized
lipids. These findings suggest that histamine synthesized in the
arterial wall participates in the initiation and progression of
atherosclerosis and that IL-4 can act as an important inhibitory
and/or stimulatory factor in the function of monocytes/macro-
phages modulated by histamine in relation to the process of
atherosclerosis. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Histamine induces reversible constriction of vascular and
non-vascular smooth muscle cells (SMC) and causes micro-
vascular vasodilatation and increased permeability of venules
[1,2], endothelial cells contraction [3], gap formation [4], aller-
gic reactions [5], and modulation of gastrointestinal function
[6] and of neurotransmission [7]. Histamine is released from
dense granules in mast cells and basophils, which cells are
located within the connective tissue and are prevalent along
the mucosal surface of the lungs and gastrointestinal tract and
in the dermis of the skin [8]. Three types of histamine-speci¢c
receptors are known, H1, H2, and H3 [9^11], and histamine
acts on the vasculature by binding mainly to speci¢c H1 re-
ceptors in the vascular wall.
In previous studies [12,13], we demonstrated that histamine
synthesized by mast cells is involved in the processes of re-
modeling of the arterial intima via its ability to stimulate the
proliferation of SMC and production of matrix metallopro-
teinases (MMPs) and that the density of histamine receptors
in SMC in the aorta and coronary artery increased in relation
to the progress of atherosclerosis. In addition, we also re-
ported that monocytes/macrophages derived from peripheral
blood expressed histamine receptors and that during matura-
tion from monocytes to macrophages, a switch of histamine
receptor expression from H2 to H1 took place [14]. These
¢ndings led us to consider that the large number of histamine
receptors expressed widely participate not only in pathological
but also in physiological events and that three speci¢c recep-
tors share functions of histamine, even within the vascular
wall. Indeed, an increased number of mast cells have been
found in the arterial intima containing advanced atheroscler-
otic foci [15] and in the adventitia of the involved artery in
patients with coronary spasms and associated vasospasm [16].
Histamine is produced by histidine decarboxylase (HDC),
which is the rate-limiting enzyme that generates histamine
from histidine through a single enzymatic reaction [17]. In
addition to being produced by mast cells/basophils, histamine
is also synthesized in T lymphocytes and monocytes/macro-
phages [18,19], which are important cell types responsible for
the progression of atherosclerosis [20^23]. Since compared
with the relatively lower number of mast cells, numerous mac-
rophages and T lymphocytes are commonly aggregated in
and/or around an atheroma, these cell types may be more
important sources of histamine than mast cells in atheroscler-
otic foci. Therefore, we investigated the expression, localiza-
tion and regulation of the HDC gene in the human arterial
wall to check other possible sources for histamine in the site.
On the other hand, it is well known that cytokines, which
are produced by in¢ltrating monocytes/macrophages and Th1
and Th2 type lymphocytes, play an important role in the
pathogenesis of allergic in£ammation in the arterial wall
[21,22,24]. Among them, we found that interleukin-4 (IL-4)
inhibits the growth of SMC and stimulates the production
of MMPs [23], suggesting that IL-4 synthesized by T cells in
the arterial intima may participate in the regression and pre-
vention of atherosclerosis. In the present communication, in
addition to examining the localization of HDC in the arterial
intima, we also discussed the e¡ects of histamine and IL-4 on
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the function of monocytes/macrophages in relation to athero-
sclerosis.
2. Methods and materials
2.1. Chemicals
Tetradecanoylphorbol 13-acetate (TPA) and phytohemagglutinin
(PHA) were obtained from Sigma (St. Louis, MO, USA). Human
recombinant IL-4 was from Peprotech (London, UK). Lipofectin re-
agent for plasmid transfection (DIMRIE-C) was purchased from Gib-
co BRL (Grand Island, NY, USA).
2.2. Cell culture
The human T cell leukemic cell line (Jurkat cells) and a human
monocytic leukemic cell line (U937 cells) used were obtained from
ATCC and maintained in RPMI 1640 (Gibco BRL, Grand Island,
NY, USA) with 10% fetal calf serum (FCS; ICN, Irvine, CA, USA),
100 U/ml of penicillin, and 2.5 Wg/ml of fungizone at 37‡C in an
atmosphere of 95% air and 5% CO2 in the presence or absence of
histamine, IL-4, TPA and/or PHA.
2.3. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNAs extracted from Jurkat or U937 cells with Trizol re-
agent (Gibco BRL) were subjected to the reverse transcriptase reac-
tion and used as templates for PCR ampli¢cation of HDC cDNA.
Autopsied materials from human aortas were also used for the RT-
PCR, as described previously [14], which used speci¢c primers (for-
ward 5P-CAAGCACATGTCAGACATGG-3P and reverse 5P-TGAA-
CAGGAAGGAGGACAGA-3P) of the human HDC gene (GenBank
M60445) for the ampli¢cation. Total RNA (5 Wg) was exposed to
SuperScript II RNase H reverse transcriptase (1000 U; Gibco BRL)
in the presence of random primer (500 ng), dNTP (0.9 mM each), and
¢rst-strand bu¡er in a total volume of 50 Wl. The reaction was allowed
to continue for 1 h at 37‡C. A 1-Wl aliquot of each reaction mixture
was then subjected to PCR using speci¢c primers. Denaturation, an-
nealing and extension temperatures and time were 94‡C for 1 min,
60‡C for 30 s, and 72‡C for 1 min, respectively, for 35 cycles. On
completion of the PCR, the ampli¢ed DNA fragments of RT-PCR
(589 bp from +1225 to +1813) were subcloned in a pGEM-T Easy
vector (Promega, Madison, WI, USA), and the puri¢ed DNA was
analyzed with an ALF DNA sequencer (Pharmacia Biotech, Uppsala,
Sweden) to con¢rm their speci¢c sequences.
2.4. Northern blotting
Total RNAs (10 Wg) were extracted from cultured cells stimulated
with TPA and/or PHA for 24 h in the presence of IL-4 and electro-
phoresed in 1% agarose/formaldehyde denaturing gel, blotted onto
Geenscreen plus (DuPont, Boston, MA, USA), and prehybridized
for 30 min at 68‡C with QuickHyb Hybridization solution (Strata-
gene, La Jolla, CA, USA). The amount of the HDC transcripts was
evaluated by hybridization with 32P-labeled speci¢c probes (589-bp
RT-PCR product) in the hybridization solution. After extensive wash-
ing to remove background non-speci¢c binding, the membrane was
exposed to an X-ray ¢lm overnight at 380‡C.
2.5. Cloning of HDC, LOX-1, and SR-A promoter regions
Based on the reported sequence data of the HDC (GenBank
D16583), LOX-1 (GenBank AB021922), and SR-A (GenBank
D13263) promoter regions, the cloning of 361-, 1063-, and 677-bp
fragments corresponding to nucleotides 3240 to +121, 31017 to
+36, or 3630 to +47, respectively, was conducted following PCR
using genomic DNA of the Jurkat cells or U937 cells with speci¢c
primers (HDC: forward 5P-SacI+TATTGTCTGAATCCAGGGG-
CA-3P, reverse 5P-HindIII+CCTTCTCCACAGATGGACACGC-3P ;
LOX-1: forward 5P-NheI+ACTTATGGGTCTCTCATGTAAGCG-
3P, reverse 5P-XhoI+TGAAGCAGTCACGAACTTCAA-3P ; SR-A:
forward 5P-MluI+AGAGCTCCTGACCTCAAGTGATCC-3P, reverse
5P-HindIII+CCTCATAGTATTTCAGCATCTG-3P). After each se-
quence had been con¢rmed, the fragment was ligated to a luciferase
reporter vector, pGL3-basic, at each restriction enzyme site (pHDC-
LucWt, pLOX-1-Luc, and pSR-A-Luc, respectively). Two mutated
pHDC-LucWt constructs were generated by self-ligation after ApaI
(located at +16) digestion and Klenow treatment (pHDC-LucM2),
and conversion of CT to GA (located at from +2 to +6) by site-
directed mutagenesis (pHDC-LucM1). The structures of the luciferase
reporter constructs are presented in Fig. 4A.
2.6. Transfection and luciferase assay
The Jurkat cells were transfected by a method of lipid-mediated
gene transfer according to the manufacturer’s manual (DIMRIE-C
reagent, Gibco BRL). Brie£y, the Jurkat cells (1U106) were incubated
with 3 Wg of reporter plasmid along with 0.2 Wg of SV40-L-galactosi-
dase (L-gal) plasmid and 5 Wl of the DIMRIE-C reagent in 0.4 ml of
OMTI-MEM medium (Gibco BRL). After a 5-h incubation, 0.6 ml of
RPMI 1640 with 5% FCS was added (¢nal serum concentration was
3%), and the cells were further incubated for 24 h with or without
TPA (10 ng/ml) and PHA (1 Wg/ml). IL-4 was added at the desired
time of the incubation. For U937 cells (1.4U107), 20 Wg of reporter
constructs with 0.5 Wg of SV40-L-gal were used for transfection by
electroporation (950 WF, 300 kV). After 8 h incubation with TPA and/
or IL-4, the cells were lysed with a lysis bu¡er (Tokyo Ink, Tokyo,
Japan) and mixed with luciferase substrate (Toyo Ink) for measure-
ment of the luciferase activity. To decrease the variation in the trans-
fection e⁄ciency, we transfected the cells in single batches for each
reporter plasmid, which were then separated into three wells for trip-
licate study. Further, L-gal activity was measured to monitor the
transfection e⁄ciency. Transcriptional activities were expressed as
fold activation relative to that of sham-treated cells transfected with
promoterless pGL3-basic vector.
3. Results and discussion
3.1. Expression of the HDC gene in the human aortic wall
To investigate HDC gene expression in human aortas, we
extracted total RNA samples from the aortic wall of autopsy
cases and applied them to RT-PCR, as reported previously
[23]. As shown in Fig. 1, the message of the HDC gene tran-
scription was detected in the normal intima (Fig. 1, lane N),
fatty streak or ¢brous plaque (Fig. 1, lane F), and atheroma-
tous foci (Fig. 1, lane A), whereas in lesions that had mark-
edly progressed and were accompanied by calci¢cation and
ulceration, the expression was sometimes not detectable. The
RNAs extracted from human aortic media did not contain
HDC mRNA, either. These data reveal that the HDC gene
Fig. 1. RT-PCR detection of HDC gene expression in the human
aorta. The total RNA was extracted from human aortas (four
autopsy cases) and used for RT-PCR examination. In all cases, RT-
PCR product of the HDC gene was detected in normal or slightly
thickened intima (lane N), fatty plaque (lane F), and/or atheroma-
tous area (lane A) or that with calci¢cation (lane A+) but not in
the media (lane Med). Lane M: size markers.
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is expressed in the aortic intima in relation to the progression
of atherosclerosis.
3.2. Localization of HDC in the human arterial wall
Immunohistochemical staining with antibodies against
HDC, CD68 (a macrophage marker), KSMA (a smooth
muscle cell marker), and CD45RO (a T cell marker), revealed
that the production of HDC occurred mainly in monocytes/
macrophages and in a lesser number of T cells in the intima of
the aorta (Fig. 2) and coronary artery. HDC could not be
detected in SMC in either the intima or the media. Identi¢ca-
tion of these HDC-positive cell types was con¢rmed by the
result that they also reacted positively with antibodies against
CD68 or CD45RO but not with anti-KSMA (not shown).
These ¢ndings con¢rm those of the RT-PCR experiments
and suggest that the transcription and translation of the
HDC gene in the arterial intima participate in atherosclerotic
processes in the arterial wall. Unlike mast cells, monocytes
and T cells do not have many granules containing various
kinds of in£ammatory mediators. Histamine synthesized in
these cell types could be directly and continuously secreted
and could function in an autocrine and/or paracrine way in
the site.
3.3. Expression of the HDC gene in monocytes/macrophages
and in T cell lines
Next, to address which types of cells potentially express the
HDC gene and to con¢rm the results of the immunohisto-
chemical staining, we used T cells (Jurkat) and U937 cells
for RT-PCR and Northern blot experiments. RT-PCR dem-
onstrated that Jurkat cells did not express the HDC gene
under normal culture conditions (Fig. 3A, lane 1). Upon stim-
ulation of Jurkat cells with both TPA (10 ng/ml) and PHA
Fig. 2. Immunohistochemical staining of HDC in atherosclerotic foci in both human coronary artery. Light microscopic photographs show
atheromatous plaques (A and B) containing large numbers of macrophages (arrows) and a lesser number of lymphocytes (arrowheads) in hu-
man aortic intima (hematoxylin^eosin-stained slides). Immunohistochemical staining revealed strongly positive staining for HDC in the cells
forming the atheromatous foci but not in the medial smooth muscle cells (C). At higher magni¢cation, HDC-positive cells, i.e. macrophages
(arrows) and lymphocytes (arrowheads), are more clearly seen (D). Magni¢cation: 30U for A and C and 150Ufor B and D.
Fig. 3. Expression of the HDC gene in cultured cells. A: RT-PCR
analysis reveals HDC gene expression in Jurkat and U937 cells. Jur-
kat cells did not express the HDC gene under normal culture con-
ditions (lane 1), whereas in U937 cells, a certain amount of its ex-
pression was detected under normal culture conditions (lane 4).
Upon stimulation with 10 ng/ml TPA and 1 Wg/ml PHA, Jurkat
cells appeared to express the HDC gene dramatically (lane 2), and
the addition of IL-4 suppressed this up-regulation (lane 3). In U937
cells, IL-4 (lane 6) also reduced up-regulation of HDC gene expres-
sion caused by TPA (lane 5). B: Northern blot analysis of HDC
mRNA in Jurkat and U937 cells. No certain amount of HDC
mRNA was detected in either Jurkat (lane 1) or U937 cells (lane 5)
under normal culture conditions, or even after the addition of 5 ng/
ml of IL-4 (lanes 2 and 6). TPA (10 ng/ml) and PHA (1 Wg/ml) or
TPA alone stimulated transcription of the HDC gene in both Jurkat
and U937 cells (lanes 3 and 7, respectively). The addition of IL-4
(5 ng/ml) reduced the up-regulation of the HDC gene transcription
by TPA/PHA (lanes 4 and 8).
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(1 Wg/ml) for 16 h, HDC gene transcription was enhanced
dramatically (Fig. 3A, lane 2), whereas this up-regulation
was suppressed by addition of IL-4 (5 ng/ml) with the TPA
and PHA (Fig. 3A, lane 3). Except for a certain amount of the
HDC mRNA transcripts in untreated U937 cells, the data on
U937 cells were similar to those on Jurkat cells.
To con¢rm these results further, we performed Northern
blotting. With stimulation by both TPA and PHA for 16 h,
the HDC mRNA was extensively expressed in the Jurkat cells
(Fig. 3B, lane 3), whereas no mRNA was detected in non-
treated cells (Fig. 3B, lane 1) or in cells treated with IL-4 (Fig.
3B, lane 2) for 16 h. In contrast, treatment with IL-4 for 16 h
apparently suppressed the up-regulation of the HDC mRNA
by TPA and PHA (Fig. 3B, lane 4). On the other hand, in
Northern blotting of U937 cells, HDC gene expression was
pronounced by TPA alone (Fig. 3B, lane 7), and the addition
of IL-4 suppressed the TPA-stimulated HDC gene expression
(Fig. 3B, lane 8).
These data con¢rm that the HDC gene is expressed by
activated T cells and by a monocyte/macrophage lineage in
the process of di¡erentiation and that IL-4 is an inhibitory
factor, even with respect to the expression of the HDC gene.
3.4. Luciferase reporter assay
To address whether IL-4 transcriptionally down-regulates
the HDC gene in the Jurkat cells, we constructed pHDC-
LucWt. As shown in Fig. 4A, the pHDC-LucWt construct
included the minimal enhancer element(s) originally respon-
sive to gastrin and TPA (gastrin-responsive elements, GAS-
RE) [25]. In our preliminary study, the pHDC-LucWt con-
struct in Jurkat cells was su⁄ciently stimulated by TPA/PHA.
Maximal transcriptional activity from the pHDC-LucWt re-
porter construct by stimulation with TPA/PHA was obtained
at 24 h after transfection of the Jurkat cells (data not shown),
and so further studies were performed with a ¢xed time of
stimulation with TPA/PHA (24 h) and various times of IL-4
treatment. After transfection with the reporter constructs by
lipid-mediated gene transfer, the Jurkat cells were stimulated
with 10 ng/ml of TPA and 1 Wg/ml of PHA for 24 h with a
¢nal 12-h treatment with 10 ng/ml of IL-4, and then the lu-
ciferase activity was measured.
IL-4 stimulation alone did not have any e¡ect on the pro-
moter activity of any of the constructs (Fig. 4B, lane 2).
Whereas TPA/PHA stimulation enhanced the promoter activ-
ities from pHDC-LucWt (four-fold over the basal activity)
and pHDC-LucM2 (two-fold), pHDC-LucM1 had no en-
hanced transcriptional activity over the basal level (Fig. 4B,
lane 3). By treatment with IL-4 at 12 h before cell harvesting
for the luciferase assay, HDC promoter activity was reduced
to 75% with pHDC-LucWt, but no reduction was detected in
pHDC-LucM2 (Fig. 4B, lane 4). In the U937 cells, the max-
imal promoter activity was observed at 8 h after electropora-
tion when stimulated with TPA, whereas treatment with IL-4
did not reduce the promoter activity from the pHDC-LucWt
construct (Fig. 4C). The activity of the pHDC-LucM2 con-
struct had the same basal level as pHDC-LucWt, but no IL-4
or TPA response was observed. In the cells transfected with
pHDC-LucM1, the basal promoter activity was less than 50%
Fig. 4. Luciferase reporter assay of the HDC gene in Jurkat or U937 cells. A: Schematic presentation of HDC promoter constructs, which con-
tain GAS-RE1 and GAS-RE2. pHDC-LucWt: 361 bp, from the SacI site (3240) to the HindIII site (+121); pHDC-Luc M1: mutant with a
two-nucleotide substitution of CT to GA at the core motif in RE1; pHDC-LucM2: deletion of four nucleotides (GGCC) from the core motif
(ApaI restriction enzyme site) in RE2. B: Luciferase reporter assay of the HDC gene in Jurkat cells. Open column: pHDC-LucWt; hatched
column: pHDC-LucM2; closed column: pHDC-LucM1; 1: untreated, basal levels; 2: treated with IL-4 (10 ng/ml); 3: treated with TPA (10
ng/ml) and PHA (1 Wg/ml); 4: treated with IL-4 (10 ng/ml)+TPA (10 ng/ml)/PHA (1 Wg/ml). C: Luciferase reporter assay of the HDC gene in
U937 cells. Open column: pHDC-LucWt; hatched column: pHDC-LucM2; closed column: pHDC-LucM1; 1: untreated, basal levels; 2: treated
with IL-4 (10 ng/ml); 3: treated with TPA (10 ng/ml); 4: treated with IL-4 (10 ng/ml)+TPA(10 ng/ml).
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of that for pHDC-LucWt, and the low activities remained
following IL-4 and/or TPA treatments.
In the time course of the e¡ect of IL-4 in Jurkat cells, the
TPA/PHA-induced promoter activities from pHDC-LucWt
and pHDC-LucM2 constructs showed 60^70% reduction 3 h
after treatment with IL-4 and recovered to 100% and 90% of
the control level 12 and 24 h later, respectively (Fig. 5A). The
result of RT-PCR paralleled those of the luciferase reporter
assay (Fig. 5B).
These analyses show that IL-4 suppressed transcriptionally
HDC gene expression in Jurkat cells. This down-regulation of
HDC mRNA by IL-4 was dose-dependent in both RT-PCR
and Northern blot analyses (data not shown).
The reporter gene for HDC containing GAS-RE was com-
posed of RE1 and RE2 regions. Our data revealed that RE1 is
more responsible for the expression of the gene than RE2, as
reported previously [26]. The deletion analysis of the human
HDC gene promoter region showed that the cis-acting DNA
sequence responsible for gastrin-mediated transactivation is
located in a region (+2 to +24) downstream of the transcrip-
tional start site (+1), which is called the gastrin-response ele-
ment (GAS-RE), by which the e¡ect of phorbol ester might be
mediated.
3.5. Reporter assay of scavenger receptors
Next, we investigated whether in situ histamine production
is involved in the function of monocytes/macrophages that
migrated into the arterial wall. The scavenger activity toward
modi¢ed lipid that accumulates in the arterial intima is one of
the most important functions of monocyte/macrophages.
Therefore, we constructed the promoter regions of the type
A scavenger receptor (SR-A) and the LOX-1 genes to check
the e¡ects of histamine and IL-4 on the promoter activity of
these genes. As shown in Fig. 6, in untreated U937 cells or in
Fig. 5. Time course of e¡ect of IL-4 on luciferase activity and on RT-PCR product in Jurkat cells. A: After transfection with pHDC-LucWt
or M2, the cells stimulated by TPA and PHA were incubated with 10 ng/ml of IL-4, and then luciferase activity was measured. Note that 3^6
h after incubation with IL-4, luciferase activity markedly decreased and then recovered gradually (open circle: pHDC-LucWt; closed circle:
pHDC-LucM2). B: Upon the stimulation of Jurkat cells with 10 ng/ml of IL-4, RT-PCR revealed results that paralleled those of the luciferase
reporter assay.
Fig. 6. E¡ects of histamine and IL-4 on function of macrophages. Luciferase reporter assay of the SR-A and the LOX-1 gene in U937 cells
was conducted. After transfection with pSR-A-Luc or pLOX-1-Luc by electroporation (Gene Pulsar II, Bio-Rad, Hercules, CA, USA), the cells
were stimulated with 100 WM histamine or 10 ng/ml of IL-4 for 8 h, and then the luciferase activity was measured. The promoter activity for
pSR-A-Luc failed to respond to either histamine or IL-4 in U937 cells, even after TPA treatment. Histamine and IL-4, however, stimulated the
cells to up-regulate the promoter activity of the LOX-1 gene, even after incubation with 10 ng/ml TPA.
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those treated with TPA for 24 h followed by a 48-h starvation,
histamine up-regulated markedly and dramatically the pro-
moter activity of the LOX-1 gene, which encodes a lectin-
like oxidized low-density lipoprotein (LDL) receptor, whereas
it failed to stimulate the activity of the SR-A promoter. Un-
expectedly, IL-4 also enhanced the promoter activity of the
LOX-1 gene in particular, in TPA-treated cells, suggesting
that histamine enhanced the LOX-1 gene in monocytes,
whereas IL-4 stimulated mature U937, i.e. macrophages, to
express the gene. From these data taken together, we think
that histamine and IL-4 biosynthesized in the arterial intima
stimulate monocyte/macrophages to phagocytose oxidized
LDL, resulting in the formation of foam cells.
4. Discussion
Our data demonstrated that via HDC activity, monocytes/
macrophages and T cells have the ability to biosynthesize and
to secrete histamine in an autocrine and/or paracrine manner
in the arterial intima. Based on our data, histamine synthe-
sized in the site can stimulate monocytes/macrophages to ex-
press the LOX-1 gene, indicating that histamine acts on
monocytes/macrophages to phagocytose and accumulate oxi-
dized LDL, which accumulation is an essential event of athe-
rosclerosis. We reported previously that histamine stimulates
SMC to proliferate and to produce MMPs via the H1 receptor
[13] and that during maturation of the cells of the monocyte/
macrophage lineage, dominant expression of the histamine
receptor changes from H2 to H1 [14]. Since the e¡ect of his-
tamine on up-regulation of the LOX-1 gene was stronger in
untreated U937 cells than in cells treated with TPA, the his-
tamine H2 receptor should participate in the up-regulation of
the LOX-1 gene in these cells. Our RT-PCR experiments re-
vealed that the SR-A gene, but not the LOX-1 gene, was
constitutively expressed under normal culture conditions
(data not shown). Regulation of the LOX-1 gene seems to
be more critical and complex as compared with that of other
scavenger receptors such as SR-A and B [27]. Therefore we
think that among several scavenger receptors, LOX-1 may
especially be involved in the function of monocytes/macro-
phages in pathological processes including atherosclerosis.
We reported earlier an inhibitory e¡ect of IL-4 on prolifer-
ation of SMC and its stimulatory e¡ect on MMP production
[23]. Similarly, the present study showed that IL-4 acts also as
a suppressor of histamine synthesis, and as a stimulator of
LOX-1 gene expression. Unlike untreated U937, upon activa-
tion with TPA, the e¡ect of IL-4 on LOX-1 gene expression
was more pronounced. Consequently, we consider that mature
monocytes, i.e. macrophages, could be more sensitive to IL-4
to express the LOX-1 gene. Interestingly, it was reported that
histamine can inhibite T cells to produce IL-4 [24,28]. Thus,
there seems to be a complicated interaction between mono-
cyte/macrophages and T cells via histamine and IL-4 produc-
tion in the arterial intima.
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